{
    "name": "peanut oral allergen powder",
    "comment": "Rx",
    "other_names": [
        "Palforzia",
        "peanut Arachis hypogaea allergen powder-dnfp"
    ],
    "classes": [
        "Allergen Immunotherapy"
    ],
    "source": "https://reference.medscape.com/drug/palforzia-peanut-oral-allergen-powder-1000341",
    "pregnancy": null,
    "lactation": null,
    "warnings": {
        "black_box_warning": {
            "common": [
                "Can cause anaphylaxis, which may be life-threatening and can occur at any time during therapy",
                "Prescribe injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use",
                "Do not administer to patients with uncontrolled asthma (contraindicated)",
                "Dose modifications may be necessary following an anaphylactic reaction",
                "Observe patients during and after administration of initial dose escalation and the first dose of each up-dosing level, for at least 60 minutes",
                "Owing to anaphylaxis risk, available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Palforzia REMS"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Uncontrolled asthma",
                "History of eosinophilic esophagitis and other eosinophilic GI disease"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Anaphylaxis",
                    "description": [
                        "Can cause anaphylaxis, which may be life-threatening",
                        "Anaphylaxis was reported during all phases of dosing, including maintenance and in patients who have undergone recommended up-dosing and dose modification procedures",
                        "Do not initiate in patients who have had severe or life-threatening anaphylaxis within the previous 60 days",
                        "All initial dose escalation doses and the first dose of each up-dosing level must be administered under observation in a healthcare setting that is able to manage severe allergic reactions, including anaphylaxis",
                        "Patients may be more likely to experience allergic reactions following administration in the presence of cofactors such as exercise, hot water exposure, intercurrent illness (eg, viral infection), or fasting; other potential cofactors may include menstruation, sleep deprivation, NSAID use, or uncontrolled asthma",
                        "Consider dose reduction and dose reescalation based on clinical judgment"
                    ]
                },
                {
                    "type": "REMS program",
                    "description": [
                        "Owing to anaphylaxis risk, available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Palforzia REMS",
                        "www.palforziarems.com or 1-844-PALFORZ (1-844-725-3679)"
                    ]
                },
                {
                    "type": "Asthma",
                    "description": [
                        "Uncontrolled asthma is a risk factor for a serious outcome, including death, in anaphylaxis",
                        "Ensure patients with asthma have their asthma under control before initiating immunotherapy",
                        "Temporarily withhold peanut oral allergen powder for an acute asthma exacerbation; following exacerbation resolution, resume cautiously according to dose interruption instructions",
                        "Reevaluate patients who have recurrent asthma exacerbations and consider discontinuation",
                        "Peanut oral allergen powder has not been studied with severe asthma, persistently uncontrolled asthma, or patients on long-term systemic corticosteroid therapy"
                    ]
                },
                {
                    "type": "Eosinophilic GI disease",
                    "description": [
                        "12 of 17 patients who underwent esophagogastroduodenoscopy (EGD) examination were diagnosed with biopsy-confirmed eosinophilic esophagitis while receiving peanut oral allergen powder",
                        "Symptomatic improvement reported in all 12 patients following discontinuance of peanut oral allergen powder",
                        "Discontinue peanut oral allergen powder and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent GI symptoms, including dysphagia, vomiting, nausea, gastroesophageal reflux, chest pain, or abdominal pain"
                    ]
                },
                {
                    "type": "GI adverse effects",
                    "description": [
                        "GI adverse reactions, including abdominal pain, vomiting, nausea, oral pruritus, and oral paresthesia, were commonly reported during clinical trials",
                        "Consider dosage modification for patients who report these reactions",
                        "For severe or persistent GI symptoms, consider a diagnosis of eosinophilic esophagitis"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Abdominal pain",
            "percent": "26.1"
        },
        {
            "name": "Abdominal pain",
            "percent": "67.1"
        },
        {
            "name": "Throat irritation",
            "percent": "40.3"
        },
        {
            "name": "Vomiting",
            "percent": "36.5"
        },
        {
            "name": "Skin pruritus",
            "percent": "32.5"
        },
        {
            "name": "Nausea",
            "percent": "32.3"
        },
        {
            "name": "Cough",
            "percent": "31.9"
        },
        {
            "name": "Oral pruritus",
            "percent": "31.2"
        },
        {
            "name": "Skin urticaria",
            "percent": "28.4"
        },
        {
            "name": "Rhinorrhea",
            "percent": "20.9"
        },
        {
            "name": "Sneezing",
            "percent": "20.2"
        },
        {
            "name": "Throat tightness",
            "percent": "14.1"
        },
        {
            "name": "Oral paresthesia",
            "percent": "13.6"
        },
        {
            "name": "Wheezing",
            "percent": "12.3"
        },
        {
            "name": "Abdominal pain",
            "percent": "29"
        },
        {
            "name": "Skin urticaria",
            "percent": "20.3"
        },
        {
            "name": "Cough",
            "percent": "19.7"
        },
        {
            "name": "Oral pruritus",
            "percent": "16.5"
        },
        {
            "name": "Vomiting",
            "percent": "16.1"
        },
        {
            "name": "Rhinorrhea",
            "percent": "14.8"
        },
        {
            "name": "Nausea",
            "percent": "14.5"
        },
        {
            "name": "Skin pruritus",
            "percent": "14.5"
        },
        {
            "name": "Throat irritation",
            "percent": "13.9"
        },
        {
            "name": "Sneezing",
            "percent": "10.6"
        },
        {
            "name": "Throat irritation",
            "percent": "9.3"
        },
        {
            "name": "Oral pruritus",
            "percent": "8.7"
        },
        {
            "name": "Nausea",
            "percent": "8.5"
        },
        {
            "name": "Skin pruritus",
            "percent": "7.9"
        },
        {
            "name": "Skin urticaria",
            "percent": "3.9"
        },
        {
            "name": "Sneezing",
            "percent": "3.4"
        },
        {
            "name": "Vomiting",
            "percent": "3.1"
        },
        {
            "name": "Cough",
            "percent": "2.5"
        },
        {
            "name": "Throat tightness",
            "percent": "2.5"
        },
        {
            "name": "Oral paresthesia",
            "percent": "1.8"
        },
        {
            "name": "Rhinorrhea",
            "percent": "1.3"
        },
        {
            "name": "Anaphylactic reaction",
            "percent": "9.1"
        },
        {
            "name": "Dyspnea",
            "percent": "7.6"
        },
        {
            "name": "Ear pruritus",
            "percent": "5.9"
        },
        {
            "name": "Anaphylactic reaction",
            "percent": "8.7"
        },
        {
            "name": "Oral paresthesia",
            "percent": "7.4"
        },
        {
            "name": "Throat tightness",
            "percent": "6.5"
        },
        {
            "name": "Wheezing",
            "percent": "6.1"
        },
        {
            "name": "Dyspnea",
            "percent": "5.5"
        },
        {
            "name": "Ear pruritus",
            "percent": "2.3"
        },
        {
            "name": "Anaphylactic reaction",
            "percent": "0.7"
        },
        {
            "name": "Ear pruritus",
            "percent": "0.7"
        },
        {
            "name": "Wheezing",
            "percent": "0.6"
        },
        {
            "name": "Dyspnea",
            "percent": "0.3"
        }
    ]
}